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S U M M A R Y
Objective: To detect and characterize pertactin-negative Bordetella pertussis in Canada, especially for
isolates collected in recent years.
Methods: A total of 224 isolates from the years 1994–2013 were screened by Western immuno-blot for
expression of pertactin. Pertactin-negative isolates were characterized by serotyping, pulsed-ﬁeld gel
electrophoresis (PFGE), and genotyping of their pertactin, ﬁmbriae 3, pertussis toxin subunit 1, and
pertussis toxin gene promoter region, as well as the complete sequence of the pertactin gene.
Results: Twelve isolates were pertactin-negative, giving an overall prevalence of 5.4%. However, no such
isolate was found prior to 2011 and 17.8% of 62 isolates examined in 2012 were pertactin-negative. Ten
pertactin-negative isolates contained a signiﬁcant mutation in their pertactin (prn) genes. IS481 was
found in the prn genes of eight isolates, while a single point mutation occurred either in the coding region
(resulting in a premature stop codon) or in the promoter region (preventing gene transcription) in two
other isolates. PFGE analysis also showed multiple proﬁles suggesting that several independent genetic
events might have led to the emergence of these pertactin-negative strains rather than expansion of a
single clone.
Conclusions: As reported elsewhere, pertactin-negative B. pertussis has emerged in Canada in recent
years, notably in 2012. This coincided with an increase in pertussis activity in Canada. A further
systematic study with a larger geographical representative sample is required to determine how these
vaccine-negative strains may contribute to the overall changing epidemiology of pertussis in Canada.
Crown Copyright  2014 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).
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Whooping cough, or 100 days cough in Chinese, is caused by the
bacterium Bordetella pertussis. Although whooping cough used to
be mainly a childhood disease, it now also occurs in adolescents
and adults, with a worldwide distribution. A pertussis vaccine was* Corresponding author. Tel.: +1 204 789 6020; fax: +1 204 789 2018.
E-mail address: raymond.tsang@phac-aspc.gc.ca (Raymond S.W. Tsang).
http://dx.doi.org/10.1016/j.ijid.2014.08.002
1201-9712/Crown Copyright  2014 Published by Elsevier Ltd on behalf of International 
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).introduced in Canada as early as 1943. Unlike some vaccines that
target only certain serotypes or serogroups, both the whole-cell
and the acellular pertussis vaccines are believed to be universally
effective in preventing pertussis caused by all strains of B.
pertussis. Despite this fact and the long history of immunization
programs in many countries, pertussis continues to be a vaccine-
preventable disease with a high number of cases and outbreaks
reported periodically – as recently as 2012 in the USA, UK,
Australia, Canada1–4 – resulting in deaths in infants too young to be
immunized or those who have not completed the schedule of allSociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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introduced as an indirect way to protect the newborn and infants.5
Research in areas to improve immune-protection, such as
changing the current vaccine formula to increase its immunoge-
nicity and duration of protection, altering the schedules of
immunization in order to optimize the protection period, and
even the development of newer vaccines, are all being examined.
These suggested changes/interventions are based on the premises
that recent observations have suggested the inferior immunoge-
nicity of the acellular pertussis vaccine versus the pertussis whole-
cell vaccine,6 and the rapid decline of immunity offered by booster
doses of acellular vaccines.7,8
Potential reasons for the continued presence of pertussis
disease activity in highly vaccinated populations have been
discussed elsewhere and include increased awareness and testing
by front-line health care providers, improved laboratory diag-
nostics, waning vaccine immunity, suboptimal acellular pertussis
vaccines, and changes in the B. pertussis bacterial population.
Strains that produce an increased amount of pertussis toxin such as
the ptxP3 strain9,10 and strains that do not have a perfect match
with the vaccine (lacking or not expressing vaccine components)
have been described.11–16
After decades of pertussis vaccination programs in infants,
followed by the more recently introduced acellular pertussis
vaccines in school-aged children, adolescents, and adults, the
incidence of pertussis in Canada reached a record low of 2 cases per
100 000 population in 2011.2 However, a sharp increase in
pertussis incidence (13.9 per 100 000 population) was reported in
Canada in 2012 due to increases in reported cases in nine different
provinces and territories (British Columbia, Alberta, Manitoba,
Ontario, Que´bec, New Brunswick, Nova Scotia, Prince Edward
Island, and Yukon),2 with some populations reporting the highest
incidence rates in North America.17
Although Canada does not have a formal laboratory surveillance
program for pertussis, the National Microbiology Laboratory
(NML) carries out periodic studies in collaboration with provinces
and territories to examine strain characteristics.13,18,19 The
molecular characteristics of Canadian pertussis strains are similar
to those described in other countries.3,9,14–16 First detected and
reported in France in 2007,12 vaccine antigen-negative B. pertussis
strains, particularly pertactin-deﬁcient strains, have now been
observed in different parts of the world,20–23 including the USA.24
The objectives of this article are to report on pertactin-negative B.
pertussis isolates in Canada and the characteristics of these isolates,
as well as how they may contribute towards the overall
epidemiology of pertussis in Canada.
2. Materials and methods
2.1. Bacterial standard strains and clinical isolates
Reference strains for studies on pertactin expression were
obtained from the American Culture Collection (Rockville, MD,
USA). B pertussis clinical isolates were provided by provincial
public health laboratories for serotyping and genetic characteriza-
tion either as part of a planned study,13,18,19 or as ad hoc activity for
outbreak investigation (see also the ‘Results and discussion’
section). Only isolates from the culture collection of the NML
were included in this study. These included 100% of the B. pertussis
collection from recent years (2007–2013), although only small
numbers were tested in each of those years (ranging from 5 in
2013 to 62 in 2012). Nevertheless, outbreak strains from British
Columbia (2012) and Saskatchewan (2010) were included. The
number of isolates tested per year during the period 1994–2006
ranged from a low of 2 in 2000 to 19 in 2005. A list of the strainsincluded in this study can be found in the Supplementary Material
(Table S1).
In total we examined 224 B. pertussis isolates collected in
different parts of Canada between 1994 and 2013. Sixty-nine
isolates were from the period 1994–2005 and represented 12.3% of
the NML B. pertussis collection from that period. One hundred and
forty-two isolates were from the years 2006–2013 and represented
98.6% of the NML B. pertussis collection from that period. The year
of isolation was not available for 13 of the tested isolates.
2.2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and Western immuno-blot
Western immuno-blot analysis was adapted from previously
described procedures,23,25 using sheep anti-pertactin antiserum
purchased from The National Institute of Biological Standards and
Control (Hertfordshire, UK). B. pertussis cells from approximately
one-eighth of a loopful of a 48-h culture on a Bordet Gengou agar
plate were suspended in 200 ml phosphate buffered saline (PBS).
Ten microlitres of the cell suspension was added to 10 ml of SDS-
PAGE sample buffer (Bio-Rad Canada, Montreal, Quebec, Canada),
and this was heated at 95 8C for 10 min. The lysate was separated
using SDS-PAGE. Samples were run against a pre-stained Precision
Plus Protein Dual Color Ladder (BioRad Canada), with a positive
control strain (B. pertussis ATCC 9797) and a negative control
(Bordetella avium ATCC 35086). Proteins resolved by SDS-PAGE
were transferred onto a polyvinylidene diﬂuoride (PVDF) mem-
brane, which was blocked overnight with 5% skim milk in PBS, then
incubated with anti-pertactin antibody, diluted 1:1000, for 2 h at
37 8C. Membranes were washed with PBS with 0.05% Tween 20
(Sigma Chemicals, St. Louis, USA) (PBST), then incubated with a
secondary donkey anti-sheep horseradish peroxidase (HRP)-
conjugated antibody (Jackson ImmunoResearch Laboratories
Inc., West Grove, PA, USA), diluted 1:1000, for 1 h at room
temperature. After a ﬁnal wash of four times with PBST,
membranes were developed with Metal Enhanced DAB Substrate
(Thermo Fisher Scientiﬁc, Waltham, MA, USA).
2.3. DNA sequencing
The pertactin genes in isolates determined to be pertactin-
negative by Western immuno-blot were sequenced using a
combination of in-house and previously described primer sets.24,26
The complete set of PCR primers and PCR conditions are available
from the authors. Sequences were analyzed using DNASTAR
software (DNASTAR Inc., Madison, WI, USA) and compared to the B.
pertussis prn2 gene sequence of strain B345 (GenBank accession
number AJ011092).27
2.4. Serotyping and genotyping
Serotyping was carried out by indirect whole-cell ELISA, as
described previously.28 Partial gene sequences of the pertussis
toxin subunit 1 (ptxS1), pertactin region 1 (prn), ﬁmbriae 3 (ﬁm3),
and pertussis toxin promoter region (ptxP) were performed as
described before.19 Sequence types (STs) were deﬁned based on
the combination of alleles of the ptxS1, prn, ﬁm3, and ptxP, as
described previously.19
3. Results and discussion
Of the 224 isolates examined by Western immuno-blot for
expression of pertactin, only 12 (5.4%) were found not to express
pertactin. A representative immuno-blot depicting positive and
negative results is shown in Figure 1. Of these 12 pertactin-
negative isolates, 11 were isolated in 2012 and one in 2011. Five of
Figure 1. Representative Western immuno-blot to detect the expression of
pertactin antigen in Bordetella pertussis isolates in Canada. Lane 1, Precision Plus
Protein Dual Color Ladder with the molecular weight of bands marked to the left;
lane 2, B. pertussis ATCC 9797, positive control; lane 3, Bordetella avium ATCC 35086,
negative control; lanes 4–8, test samples (lanes 4, 5, and 8 show positive results for
pertactin expression, while lanes 6 and 7 show negative results for pertactin).
Arrow indicates the position of pertactin in the Western immuno-blot.
R.S.W. Tsang et al. / International Journal of Infectious Diseases 28 (2014) 65–69 67the pertactin-negative isolates were from the province of Alberta
(all in 2012), while seven were from the province of Ontario. Five of
the pertactin-negative B. pertussis isolates belong to ST-1,
characterized by the genotype ptxS1A, prn2, ﬁm3B, and ptxP3,
while seven belonged to ST-2, characterized by the genotype
ptxS1A, prn2, ﬁm3A, and ptxP3. Isolates belonging to ST-1 and ST-2
were seen in both provinces. All 12 pertactin-negative isolates
expressed the Fim3 but not the Fim2 serotype antigen.
A genetic mutation that explained the lack of pertactin
expression was found in 10 of the pertactin-negative isolates
(Table 1). IS481 insertion sequences were found in eight strains
(66.7%), with seven located within the coding region at nucleotide
position 1613, relative to the prn2 gene sequence of B. pertussis
strain B345 (GenBank accession number AJ011092.1), and in one
strain at nucleotide position 245. In six isolates the IS elements
were found within the prn2 gene in the reverse direction, while in
two isolates they were found in the forward direction (Figure 2), as
observed previously by others (GenBank accession numbers
AB670736 and AB670737).
Besides the common mechanism of disruption of the prn gene
due to IS481, we found one isolate with a cytosine to thymine
mutation at position 1273, resulting in a premature stop codon at
amino acid position 425, which has also been observed by others.24
In another isolate, a guanine to adenine mutation was found in
the promoter region at position 162, suspected to disruptTable 1
Characteristics of 12 pertactin-deﬁcient Bordetella pertussis isolates from the provinces
Number of isolates Year of isolation Province prn mutation and nuc
1 2012 ON No mutations 
1 2012 AB No mutations 
1 2011 ON G to A mutation in pr
1 2012 ON C to T mutation at po
1 2012 AB IS481 inverted at posi
1 2012 AB IS481 at position 1613
1 2012 ON IS481 at position 1613
1 2012 AB IS481 inverted at posi
1 2012 AB IS481 inverted at posi
3 2012 ON IS481 inverted at posi
PFGE, pulsed-ﬁeld gel electrophoresis.
a Position relative to the prn2 gene of B. pertussis strain B345 (AJ011092).transcription of the gene. The mutation site identiﬁed in this strain
was equivalent to the putative 10 promoter sequence identiﬁed
by Kinnear et al.,29 to which the RNA polymerase was expected to
bind in the promoter. In the remaining two pertactin-negative
isolates, no mutation was found in their prn genes, neither in the
promoter region nor in the coding sequence, suggesting other
potential genetic defects not identiﬁed in this study.
To further deﬁne the genetic relatedness of the pertactin-
negative B. pertussis isolates, PFGE proﬁles obtained using two
restriction enzymes were analysed. With SpeI restriction enzyme,
eight different proﬁles were obtained, while with XbaI, ﬁve proﬁles
were observed. When PFGE patterns generated by the two
enzymes were combined, 10 restriction proﬁles were obtained
(Figure 3).
The epidemiology of pertussis in Canada is complex, with
widely varying rates found in the different provinces and
territories.2 This may be due in part to the different vaccine
products used as well as the different introduction dates and
schedules implemented by the different provinces and territo-
ries.30,31 Currently only two kinds of acellular pertussis vaccine are
licensed for use in Canada (http://www.phac-aspc.gc.ca/publicat/
cig-gci/introduction-eng.php). One form consists of ﬁve compo-
nents (pertussis toxoid, pertactin, ﬁlamentous hemagglutinin,
ﬁmbriae 2, and ﬁmbriae 3), while the other form consists of three
components (pertussis toxoid, pertactin, and ﬁlamentous hemag-
glutinin). Also, each acellular vaccine should be considered a
different product as different vaccines may have varying con-
centrations of pertactin as well as other targets (http://
www.who.int/biologicals/areas/vaccines/apertussis/en/).
The overall prevalence of the pertactin-deﬁcient phenotype
among B. pertussis isolates examined in Canada was 5.4% (12/224
isolates). In 2011, the prevalence was 10% (1/10 isolates) and this
increased to 17.8% (11/62 isolates) in 2012. Based on this study,
pertactin-negative strains were only found in the provinces of
Alberta and Ontario since 2011 and mainly in 2012. The percentage
of this phenotype among the isolates tested in these two provinces
in 2012 increased to 9.6% and 60% for Alberta and Ontario,
respectively. This sudden increase in the ﬁnding of pertactin-
deﬁcient B. pertussis isolates appears to coincide with increases in
pertussis activity in a number of provinces in Canada. However, the
pertactin-deﬁcient phenotype is notably absent from the outbreak
strains in Saskatchewan (2010) and British Columbia (2012), albeit
the total number of isolates examined from these outbreaks were
small (ﬁve in Saskatchewan and nine in British Columbia).
Whether the pertactin-deﬁcient phenotype might have contribut-
ed to the outbreaks in Ontario and Alberta would require further
in-depth studies matching clinical and epidemiological data with
results from the laboratory characterization of strains.
Another feature of the pertactin-negative B. pertussis isolates is
the fact that they all have the genotype ptxS1A, ptxP3, and
prn2. However, their ﬁm3 gene sequences divide them into two of Alberta (AB) and Ontario (ON) in 2011 and 2012
leotide positiona Sequence type PFGE proﬁle
ST-1 Xba 076 Spe 001
ST-2 Xba 021 Spe 003
omoter region, position –162 ST-2 Xba 071 Spe 056
sition 1273, resulting in stop codon ST-2 Xba 021 Spe 001
tion 245 ST-2 Xba 077 Spe 064
 ST-2 Xba 073 Spe 065
 ST-2 Xba 073 Spe 001
tion 1613 ST-2 Xba 021 Spe 020
tion 1613 ST-1 Xba 076 Spe 038
tion 1613 ST-1 Xba 076 Spe 004
Figure 2. Schematic diagram of the prn gene showing the various types of mutation that affect expression of the pertactin antigen. Locations of the start codon (marked in bold
italic and underlined) and the 10 promoter sequence (marked in bold and underlined) are shown (adapted from Kinnear et al., 199929). +Guanine to adenine mutation at
nucleotide position –162 leading to disruption of the –10 promoter sequence. *Cytosine to thymine mutation at nucleotide position 1273 leading to a premature stop codon
(TAG). #Insertion of the IS481 element at nucleotide position 1613 in either the forward (F) or reverse (R) direction. ++Insertion of the IS481 element at nucleotide position
245 in the reverse (R) direction.
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Figure 3. Dendrogram showing relatedness by pulsed-ﬁeld gel electrophoresis (PFGE) of 12 pertactin-deﬁcient Bordetella pertussis isolates in Canada. Isolates are identiﬁed by
sequence type (ST), prn mutation, year, and province (Prov) of isolation (Alberta, AB; Ontario, ON), as well as PFGE proﬁles generated by restriction enzymes Xba and Spe.
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and ﬁm3A genotype, respectively. The PFGE data suggest that the
pertactin-negative isolates are not clonal and this observation is
also supported by the genetic mutations that we observed in their
prn genes. The non-clonal nature of the pertactin-negative B.
pertussis strains has also been observed in Australia.23 Therefore,
our overall data suggest that the pertactin-negative isolates
probably arose from multiple independent mutations that
occurred recently. It has been hypothesized that these vaccine
antigen-negative strains probably developed as a result of vaccine
pressure, especially the acellular vaccine types that contain
pertactin as one of the few components present as opposed to
inactivated whole-cell vaccines. Whether this was related to more
intense immunization programs implemented among outbreak
communities should be considered in future studies to understand
the evolution of B. pertussis.
A major limitation of this study was the lack of systematic
collection and testing of isolates. This is due to the fact that there is
no formal laboratory surveillance program for pertussis in Canada
and, therefore, B. pertussis isolates are not routinely submitted to
the NML for strain characterization. Rather, isolates may be
submitted in an ad hoc manner during an outbreak. Even then,
bacteriological cultures may not be performed to collect viable
organisms for testing, as some jurisdictions now rely solely on PCR
to provide laboratory conﬁrmation of pertussis. This inevitably
creates an important gap in the critical information necessary to
understand the molecular epidemiology of pertussis in Canada and
results in our inability to build up a longitudinal database to
compare the evolution of strains over time. The importance of
maintaining some culture capability to identify and characterize B.
pertussis strains in order to understand the complexity of
how changes in the bacterium may contribute to the overallepidemiology of pertussis has been raised in a recent editorial that
appeared in our national communicable disease journal.17 Another
limitation of our study is the fact that there is no standardized
system to link vaccination data to cases identiﬁed in the country,
thereby limiting our ability to know if cases identiﬁed are vaccine
failures or due to other reasons.
In conclusion, pertactin-negative B. pertussis strains have been
found in Canada since 2011 and they appeared to be common in
two provinces in 2012. This initial study may provide an impetus
for the development of a more comprehensive surveillance
program for pertussis in Canada to include clinical and epidemio-
logical data, vaccination history, and laboratory characterization of
strains.
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